Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
ACET(NASDAQ:ACET) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference being held from September 8-10, 2025 in New York. Details of the event are as follows: Date: Monday, September 8, 2025 Time: 4:
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ACET(NASDAQ:ACET) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 29, 2025. Two individuals were hired by Adicet in August 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 84,000 shares of Adicet’s common stock with an exercise price of $0.72 per
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
ACETREDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2025. “We continue to make meaningful progress in our ADI-001 autoimmune Phase 1 clinical program. Site activation is progressing well with more than 20 sites currently open for
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
ACETREDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 45th Annual Canaccord Genuity Growth Conference being held from August 12-14, 2025 in Boston. Details of the event are as follows: Date: Tuesday, August 12, 2025
12 Health Care Stocks Moving In Friday's Pre-Market Session
ACET12 Health Care Stocks Moving In Thursday's After-Market Session
ACETAdicet Bio Q1 EPS $(0.31) Beats $(0.34) Estimate
ACETAdicet Bio To Give Oral Presentation For Its Preclinical ADI-270 Data At The American Society Of Gene And Cell Therapy 28th Annual Meeting
ACET12 Health Care Stocks Moving In Thursday's After-Market Session
ACETGuggenheim Reiterates Buy on Adicet Bio, Maintains $7 Price Target
ACETCitizens Capital Markets Reiterates Market Perform on Adicet Bioto Market Perform
ACETHC Wainwright & Co. Reiterates Neutral on Adicet Bioto Neutral
ACETAdicet Bio Reports Poster Presentations Highlighting ADI-270 Data At SITC 2025 Spring Scientific Meeting
ACETHC Wainwright & Co. Reiterates Neutral on Adicet Bioto Neutral
ACETThe FDA Has Granted Fast Track Designation To Adicet Bio's ADI-001 For The Potential Treatment Of Adult Patients With Systemic Sclerosis
ACETHC Wainwright & Co. Reiterates Neutral on Adicet Bioto Neutral
ACETAdicet Bio Says First Patient Dosed In The Phase 1 Clinical Trial Evaluating ADI-270 In Patients With Metastatic/Advanced ccRCC
ACETAdicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical Data
ACETHC Wainwright & Co. Reiterates Neutral on Adicet Bio
ACETReported Saturday, Adicet Bio Shared Clinical Biomarker Data On Off-The-Shelf CAR T Cell Therapy During Oral Session At ACR Convergence 2024
ACETAdicet Bio Q3 EPS $(0.34) Beats $(0.35) Estimate
ACET